Delivery Order 36F79724D0101-36C24925N0271
Award Date
12/13/24
Potential Completion Date
2/12/25
Potential Value
$314K
Federal Agency
Veterans Integrated Service Network 9
Awardee
Bristol-Myers Squibb Company
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to the U.S. Department of Veterans Affairs (VA). The contract, valued at $310,953.57, was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on December 13, 2024. The work is primarily performed at Bristol-Myers Squibb's facility in Lawrenceville, New Jersey, and the delivery order has a completion date of January 12, 2025. This award is a delivery order...
The U.S. Department of Veterans Affairs (VA) awarded a delivery order contract to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the provision of two chimeric antigen receptor (CAR) T cell therapies: BREYANZI and ABECMA. The contract, valued at $314,322.29, is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the VA Veterans Health Administration. The work is primarily performed at Bristol-Myers Squibb's...
The U.S. Department of Veterans Affairs (VA) awarded a $335,042.65 firm fixed price delivery order contract to Bristol-Myers Squibb Company for the provision of the BREYANZI chimeric antigen receptor (CAR) T cell therapy. This order is a part of Bristol-Myers Squibb's larger $12.28 billion Federal Supply Schedule (FSS) contract (36F79724D0101) with the VA, which covers a range of pharmaceutical and hematology-related products. The contract supports the VA's mission of providing advanced...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy, to patient ENR-018564. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9). The contract is a firm fixed price delivery order with a ceiling value of $310,935.67 and a performance period ending on January 5, 2025. This order is placed against...
This is a federal delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer. The $335,042.65 firm fixed price contract is for the delivery of the BREYANZI chimeric antigen receptor (CAR) T cell therapy for transplant treatment. The contract is part of Bristol-Myers Squibb's larger $12.28 billion Federal Supply Schedule contract with the VA, which provides a wide range of drugs, pharmaceuticals, and...
This is a federal contract award to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, for the delivery of the ABECMA chimeric antigen receptor (CAR) T cell immunotherapy. The award, valued at $314,322.29, is a delivery order placed against Bristol-Myers Squibb's existing Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs Veterans Health Administration (VA VHA). This multiple award FSS contract has a ceiling value of $12,278,876,570.00 and runs...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy product, to the Department of Veterans Affairs (VA) for the treatment of a veteran patient. The contract was awarded to Bristol-Myers Squibb Company, a large pharmaceutical manufacturer, and has a ceiling value of $335,042.65. The contract is a firm fixed price delivery order under Bristol-Myers Squibb's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA,...
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 9 (VISN 9) to Bristol-Myers Squibb Company, a global biopharmaceutical company, for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T-cell therapy used to treat non-Hodgkin lymphoma. The $310,953.67 firm fixed-price delivery order has an ultimate completion date of August 30, 2024. This award is a call against Bristol-Myers Squibb's existing Federal Supply Schedule...
This federal contract award is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy for treating non-Hodgkin lymphoma, to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9. The contract was awarded to Bristol-Myers Squibb Company, a global biopharmaceutical company, on a firm fixed price basis with a potential value of $310,935.67. The contract has a completion date of June 10, 2024 and is not associated with...
This federal contract award is for the delivery of ABECMA, a chimeric antigen receptor (CAR) T cell therapy, to the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9. The $314,322.29 firm fixed price delivery order was issued to Bristol-Myers Squibb Company, a global biopharmaceutical firm, under the company's existing Federal Supply Schedule (FSS) contract with the VA (Contract ID: 36F79724D0101). This FSS contract, with a $12,278,876,570.00 ceiling value,...